Nachrichten zur Amneal Pharmaceuticals Aktie

Amneal Pharmaceuticals hat sich erfolgreich vom austauschbaren Massenhersteller einfacher Nachahmermedikamente zu einem margenstarken Spezialitäten- und Biosimilar-Konzern transformiert. Mit dem...…

CareDx, Healthcare Services Group, Forum Energy Technologies, Amneal Pharmaceuticals and Caterpillar emerge as high-efficiency stocks poised for stronger returns.…

Amneal Pharmaceuticals (NASDAQ:AMRX) said on Thursday the US Food and Drug Administration has approved its romidepsin injection solution, 27.5 mg/5.5…

Amneal Pharmaceuticals stock gains on FDA approval for cancer drug…

Amneal (AMRX) delivered earnings and revenue surprises of +63.64% and +1.86%, respectively, for the quarter ended March 2026. Do the…

Amneal Pharmaceuticals (AMRX) ist ein Spezialpharmaunternehmen, welches 2026 auf eine spannende Phase beschleunigter Markteinführungen und gezielter Expansionen blickt. Das letzte…

…

Amneal Pharmaceuticals Inc (NASDAQ:AMRX) shares rose 5.7% on Friday after UBS initiated coverage with a Buy rating and a $19…

…

Truist raises Amneal Pharmaceuticals stock price target on margin focus…

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to…

BRIDGEWATER, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today…

…

Amneal Pharmaceuticals announced that the U.S. FDA has approved its iohexol injection (300 mg Iodine/mL), the first generic version of…

Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.…

BRIDGEWATER, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal”) (Nasdaq: AMRX) announced that its subsidiary,…

…

Amneal (AMRX) delivered earnings and revenue surprises of 40% and 2.71%, respectively, for the quarter ended March 2025. Do the…

Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.…

…

…

Amneal (AMRX) delivered earnings and revenue surprises of 14.29% and 6.75%, respectively, for the quarter ended June 2024. Do the…

…

The Global Muscle Relaxant Drugs Market Size was Valued at USD 3.90 Billion in 2023 and the Worldwide Muscle Relaxant…

The Global Parkinsons Disease Treatment Market Size was Valued at USD 4.91 Billion in 2023 and the Worldwide Parkinsons Disease…

The Canadian pharmaceutical market is the eighth largest in the world and accounts for 2.2 percent of the global prescription…

…

…

Amneal Pharmaceuticals said on Friday it had reached a deal valued at more than $270 million to resolve claims it…

Amneal (AMRX) delivered earnings and revenue surprises of 55.56% and 5.80%, respectively, for the quarter ended March 2024. Do the…

The Global Testosterone Replacement Therapy Market Size was Valued at USD 1.98 Billion in 2023 and the Worldwide Testosterone Replacement…

Bausch (BHC) initiates litigation against Amneal Pharmaceuticals and its subsidiaries over a generic version of its lead drug Xifaxan.…

The Global Pregabalin Market Size was Valued at USD 1.65 Billion in 2023 and the Worldwide Pregabalin Market Size is…

Earnings call: Amneal Pharmaceuticals sees growth and diversification in 2023…

…

…

Amneal (AMRX) delivered earnings and revenue surprises of 100% and 2.17%, respectively, for the quarter ended December 2023. Do the…